成像生物标记物预测肝细胞癌免疫治疗反应的研究进展

摘要/Abstract

摘要： 肝细胞癌(HCC)是全球癌症相关死亡的第三大原因。原发性肝癌是一组肝内异质性癌症,其中HCC是最常见的肿瘤^[1],占原发性肝癌的90%。虽然病毒性肝炎仍是我国HCC发生最常见的危险因素,但NAFLD已取代病毒性肝炎成为我国最常见的慢性肝病,这也是目前非病毒性HCC迅速增长的原因。目前靶向治疗和免疫治疗成为晚期 HCC 临床研究的热点。如何筛选出免疫治疗优势人群的生物标志物,优化HCC患者的治疗方案成为了目前的研究重点。有研究表明,非病毒性HCC肿瘤细胞内脂肪变性可能是预测免疫治疗疗效的新型成像生物标志物。

关键词: 肝细胞癌, 免疫治疗, 成像生物标记物, 脂肪变性

陈克敏. 成像生物标记物预测肝细胞癌免疫治疗反应的研究进展[J]. 肝脏, 2023, 28(5): 513-514.

参考文献

[1] Villanueva A. Hepatocellular Carcinoma. N Engl J Med,2019,380(15): 1450-1462.
[2] Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol,2021,75(2): 454-461.
[3] Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy,2016,8(7): 821-837.
[4] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med,2008,359(4): 378-390.
[5] Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol,2018,15(10): 599-616.
[6] Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol, 2020,73(6): 1460-1469.
[7] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol,2018,19(7): 940-952.
[8] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med,2020,382(20): 1894-1905.
[9] Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol,2020,72(2): 215-229.
[10] Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology,2017,153(3): 812-826.
[11] Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature, 2017,541(7637): 321-330.
[12] Li F, Li C, Cai X, et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine,2021,41: 101134.
[13] Lu S, Stein JE, Rimm DL, et al. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol, 2019, 5(8): 1195-1204.
[14] Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature,2021,592(7854): 450-456.
[15] Murai H, Kodama T, Maesaka K, et al. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology,2023,77(1): 77-91.
[16] Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res,2008,68(16): 6779-6788.
[17] Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res, 2009, 69(18): 7385-92.
[18] Quigley M, Pereyra F, Nilsson B, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med,2010,16(10): 1147-1151.
[19] Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun,2013,4: 2612.
[20] Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell,2018, 33(4): 547-562.
[21] Stephen TL, Rutkowski MR, Allegrezza MJ, et al. Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity, 2014,41(3): 427-439.
[22] Cassidy FH, Yokoo T, Aganovic L, et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics,2009,29(1): 231-260.